SAN FRANCISCO: An Indian medical innovation has achieved a significant world recognition with a brand new technology coronary heart stent manufactured in India attaining a decrease failure fee in high-risk sufferers in opposition to a US-made worldwide market chief.
At a largely attended world convention of cardiologists, which concluded right here on Wednesday, well-known Indian coronary heart specialist, Dr Upendra Kaul, Chairman and Dean of Delhi’s Batra Hospital, introduced the outcomes of a trial in India named TUXEDO-2, which rigorously in contrast the brand new technology Indian-made coronary heart stent, Supraflex Cruz, in opposition to the worldwide market chief Xience of the USA.
Carried out throughout 66 Indian cardiology centres, the trial targeted particularly on a extremely advanced affected person inhabitants, akin to sufferers with diabetes and superior multi-vessel illness.
Eighty per cent of the individuals had triple vessel illness, in accordance with Dr Kaul, beneath whose management the trial was carried out.
The outcomes have been overwhelmingly optimistic for the Indian gadget, demonstrating that Supraflex Cruz was non-inferior to the established worldwide normal.
 "Is a post-Holi detox necessary or do you just need better gut awareness – Firstpost")
 "School-based HPV rollout could redefine cervical cancer prevention in India – Firstpost")
